[{"id":"lenvatinib","kind":"drug","name":"Lenvatinib","route":"/drugs/lenvatinib/","commit":"925a04b429","date":"2026-09-10","author":"Jude Gomila","message":"Primary source links (FDA label via DailyMed) for a third batch of thirty approved products","file":"src/data/spikes/rcc.ts","type":"changed","fields":[{"field":"links","after":"[{ label: \"FDA label (DailyMed)\", url: \"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Lenvatinib\" }]"}]},{"id":"lenvatinib","kind":"drug","name":"Lenvatinib","route":"/drugs/lenvatinib/","commit":"57b67248b1","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch B: clinician power tools","file":"src/data/interactions.ts","type":"added","fields":[{"field":"id"},{"field":"name"},{"field":"class"},{"field":"props"},{"field":"management"},{"field":"hepatic"},{"field":"renal"},{"field":"source"}]},{"id":"lenvatinib","kind":"drug","name":"Lenvatinib","route":"/drugs/lenvatinib/","commit":"afc6af185b","date":"2026-09-08","author":"Jude Gomila","message":"Spikes: ovarian, endometrial, cervical cancer deep dives (74 new entities with structured outcomes, dosing, toxicity, regulatory events, gui","file":"src/data/spikes/endometrial.ts","type":"added","fields":[{"field":"id"},{"field":"name"},{"field":"brand"},{"field":"modality"},{"field":"status"},{"field":"wikipedia"},{"field":"tldr"},{"field":"summary"},{"field":"mechanism"},{"field":"mechanismSteps"},{"field":"dosing"},{"field":"toxicity"},{"field":"approvals"},{"field":"regulatoryEvents"},{"field":"targets"},{"field":"technologies"},{"field":"companies"},{"field":"cancers"},{"field":"trials"},{"field":"pathways"}]},{"id":"lenvatinib","kind":"drug","name":"Lenvatinib","route":"/drugs/lenvatinib/","commit":"06611b41fb","date":"2026-09-08","author":"Jude Gomila","message":"Spikes: SCLC, mesothelioma, urothelial, RCC deep dives with structured outcomes, dosing, toxicity, regulatory events","file":"src/data/spikes/rcc.ts","type":"added","fields":[{"field":"id"},{"field":"name"},{"field":"brand"},{"field":"modality"},{"field":"status"},{"field":"wikipedia"},{"field":"tldr"},{"field":"summary"},{"field":"mechanism"},{"field":"mechanismSteps"},{"field":"dosing"},{"field":"toxicity"},{"field":"approvals"},{"field":"targets"},{"field":"technologies"},{"field":"companies"},{"field":"cancers"},{"field":"trials"}]},{"id":"lenvatinib","kind":"drug","name":"Lenvatinib","route":"/drugs/lenvatinib/","commit":"06899fbdf4","date":"2026-09-08","author":"Jude Gomila","message":"Spikes: hepatocellular carcinoma, biliary tract cancer, neuroendocrine tumours (deep, with structured outcomes, dosing, toxicity, regulatory","file":"src/data/spikes/hcc.ts","type":"added","fields":[{"field":"id"},{"field":"name"},{"field":"brand"},{"field":"modality"},{"field":"status"},{"field":"wikipedia"},{"field":"tldr"},{"field":"summary"},{"field":"mechanism"},{"field":"mechanismSteps"},{"field":"dosing"},{"field":"toxicity"},{"field":"approvals"},{"field":"targets"},{"field":"technologies"},{"field":"companies"},{"field":"cancers"},{"field":"trials"}]}]